Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: Ricardo A. Biondi who wrote (617)	5/15/1998 11:03:00 PM
From: Beltropolis Boy	Read Replies (1) \| Respond to of 900

>Dr. Andrew Janoff, Vice President of Research and Development, >presented data showing that two of the Company's drugs in >pre-clinical trials have been tested successfully in tumor-bearing >mice. One of these drugs, a liposomal ether lipid known as TLC >ELL-12, kills cancer cells by apoptosis. hey-zeus! mice and cancer mentioned in (practically) the same sentence?!? i'm floored lipo didn't get launched into the stratosphere a la entremed. hey, was this released after the closing bell? don't put in a market order over the weekend. you could get singed. as jim cramer recently opined (don't take it too seriously, i'm posting for its chuckle value): "[Ribozyme] makes something that works in this environment -- and I don't mean the anti-cancer drug, who knows if Angiozyme, or whatever it is called, will ever work? Ribozyme Pharma makes headlines about cancer drugs, and that's just good enough in this tape."